January 27, 2014
BioTissue® Trending at 35 Percent Compound Growth, 33 Percent Unit Growth
BioTissue® therapies emerging as standard of care for eye care professionals
MIAMI, FL – January 27, 2014 – BioTissue® Inc, the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, today announced it has attained 33 percent unit growth and a 7-year compounded annual growth rate (CAGR) of 35 percent. With nearly 200,000 units shipped across all product lines since 2006 and more than 150,000 successful human transplantations, BioTissue’s products are used by eye care professionals worldwide to manage ocular surface diseases and conditions.
BioTissue’s product lines include AmnioGraft®, a biologic ocular transplantation graft; AmnioGuard®, a biologic glaucoma shunt tube graft; Prokera®, a dual-action, biologic corneal bandage that is the only FDA-cleared therapeutic device that reduces inflammation and promotes healing; and Cliradex®, an all-natural, preservative-free lid, lash and facial cleanser, which optimizes management of lid margin diseases. Cliradex is the only commercially available product that incorporates 4-Terpineol, the active component of tea tree oil that clinically demonstrated anti-inflammatory, anti-microbial, anti-bacterial, anti-fungal and miticidal properties.
“This accomplishment serves as an endorsement in BioTissue’s technology platforms, which go a long way in the treatment and management of ocular surface diseases,” said Scheffer Tseng, MD, PhD, BioTissue Inc Chairman and Chief Scientific Officer. “We are confident that the products BioTissue has developed through ongoing evidence-based research will become the new paradigm for eye care professionals seeking to improve clinical outcomes and enhance patients’ quality of life.”
The Prokera medical device brand, which includes three biologic corneal bandages – including new products Prokera Slim for mild to moderate indications, and Prokera Plus for severe indications – are the lead drivers in helping the company reach this milestone. These products cover the broad spectrum of treatment for mild to severe ocular surface diseases (OSD) such as keratitis, corneal erosion, dry eye syndrome, Stevens – Johnson syndrome (SJS) and chemical burns.
“One of the primary goals of eye care professionals is to diagnose and treat eye conditions and prevent vision loss,” says Christopher J. Rapuano, MD, Chief of the Cornea Service at Wills Eye Hospital and Cornea Society President. “BioTissue’s products increase my treatment armamentarium and are becoming important components in my practice for the management of ocular surface diseases.”
“Given the competitive biotech landscape and segmented market for ophthalmic therapies in general, achieving this kind of consistent year-over-year growth is a significant milestone,” said Tom Daniells, Chief Commercial Officer at BioTissue. “It not only highlights the profound positive impact our products have on improving patient outcomes, but also strengthens our commitment to continue developing new innovative eye care treatments to meet clinical needs in the marketplace.